Continuous renal replacement therapy in critically ill patients does not affect urinary neutrophil gelatinase-associated lipocalin levels

Ioannis Vasileiadis, Chrysoula Pipili and Serafeim Nanas

See related research by Schilder et al., http://ccforum.com/content/18/2/R78

In the present study, we assessed urinary neutrophil gelatinase-associated lipocalin (uNGAL) during 24-hour continuous renal replacement therapy (CRRT) in critically ill patients. The study was performed in accordance with the Declaration of Helsinki and was approved by the Scientific Council and the Ethics Committee of Evangelismos Hospital in Athens, Greece. Informed consent was provided by family members of the patients included in the study. Eighteen critically ill patients (13 men and five women with a mean age of 69 ± 14 years) in an interdisciplinary intensive care unit underwent continuous veno-venous hemodiafiltration (CVVHD). Three had oliguria (urine output of less than 200 mL per 12 hours). Patient characteristics at enrollment are shown in Table 1.

uNGAL was determined before CRRT onset and at 6 and 24 hours during CVVHD. uNGAL was measured by using a chemiluminescent assay with ARCHITECT technology (Abbott Diagnostics Inc., Abbott Park, IL, USA). For CVVHD, pump-driven machines - from Prisma (a brand of Gambro, Deerfield, IL, USA), Kimal (Dormagen, Germany), or Nephro-Tech (Shawnee, KS, USA) - were used with a 0.9 m² polysulfone filter. uNGAL levels did not change, whereas serum creatinine and serum cystatin C significantly decreased (Table 2). No correlation was found between uNGAL levels and the illness severity scores at inclusion.

In a study by Schilder and colleagues [1] in a previous issue of Critical Care, plasma NGAL (pNGAL) in critically ill patients was similarly not affected by RRT. No net removal of pNGAL was established, although absorption by the filter with concomitant production could not be definitively excluded. Besides an insufficient clearance through the filter, other causes could be implicated for the remaining NGAL levels.

Whereas pNGAL can come from an extra-renal source (as in sepsis [2]), uNGAL may derive mostly from local synthesis in the kidney [3]. NGAL that has been synthesized in the kidney and can be detected in urine may not efficiently enter the systemic circulation to be cleared by the filter.

Table 1 Patient characteristics (n = 18)

| Patient characteristic | Number (percentage) of patients unless noted otherwise |
|------------------------|--------------------------------------------------------|
| APACHE II score        | 19.4 ± 7.5                                              |
| SOFA score            | 9.2 ± 2.9                                               |
| SAPS                   | 69.5 ± 14.2                                             |
| Reason for admission  |                                                        |
| Trauma                 | 1 (5.5%)                                                |
| Post-operative         | 11 (61%)                                                |
| Circulatory            | 4 (22%)                                                 |
| Respiratory            | 2 (11%)                                                 |
| SIRS                   | 5 (28%)                                                 |
| Sepsis                 | 4 (22%)                                                 |
| Septic shock           | 7 (39%)                                                 |
| RIFLE                  |                                                        |
| No                     | 2 (11%)                                                 |
| Risk                   | 5 (28%)                                                 |
| Injury                 | 10 (55.5%)                                              |
| Failure                | 1 (5.5%)                                                 |
| Diabetes               | 6 (33%)                                                 |
| Vasopressors           | 11 (61%)                                                |

* Correspondence: aicusn@gmail.com
1 First Critical Care Department, Evangelismos’ General Hospital, National and Kapodistrian University of Athens, 4547, 10675 Athens, Greece
2 Full list of author information is available at the end of the article

© 2015 Vasileiadis et al; licensee BioMed Central. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

© 2015 Vasileiadis et al; licensee BioMed Central. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Another possible explanation concerns the significance of NGAL function. It has been shown that NGAL has some physiological functions such as carrying out anti-microbial activity and a protective role in the kidney [4,5]. Substituting the function of the kidney with the artificial filter does not mean that the reasons leading to the increased levels of NGAL are eliminated (for example, sepsis or, specifically for the uNGAL, the kidney damage). So regardless of the possibility that the filter cleanses the factor, the production of NGAL might be purposely preserved to carry out its physiological role.

**Table 2 Renal function biomarkers during continuous renal replacement therapy**

|                      | Before CRRT | At 6 hours | At 24 hours | P value |
|----------------------|-------------|------------|-------------|---------|
| uNGAL, ng/mL         | 1,917 ± 1,911 | 1,675 ± 1,634 | 1,661 ± 1,633 | 0.23    |
| sCr, mg/dL           | 2.8 ± 1.5   | 2.3 ± 0.9  | 1.9 ± 0.9   | <0.0001 |
| sCysC, mg/L          | 2.74 ± 0.8  | 1.97 ± 0.64 | 1.90 ± 0.8  | <0.0001 |

CRRT, continuous renal replacement therapy; sCr, serum creatinine; sCysC, serum cystatin C; uNGAL, urinary neutrophil gelatinase-associated lipocalin.

**Abbreviations**

CRRT: Continuous renal replacement therapy; CVVHD: Continuous veno-venous hemodiafiltration; NGAL: Neutrophil gelatinase-associated lipocalin; pNGAL: Plasma neutrophil gelatinase-associated lipocalin; RRT: Renal replacement therapy; uNGAL: Urinary neutrophil gelatinase-associated lipocalin.

**Competing interests**

The authors declare that they have no competing interests.

**Authors’ contributions**

IV drafted the manuscript. CP participated in the collection and analysis of the data, statistical analysis, and drafting of the manuscript. SN conceived and designed the study and revised the manuscript critically. All authors contributed substantially to the submitted work and read and approved the final manuscript.

**Author details**

1. Intensive Care Unit, First Department of Respiratory Medicine, Medical School, University of Athens, Mesogeion 152, ‘Sotiria’ Hospital, 11527, Athens, Greece.
2. First Critical Care Department, ‘Evangelismos’ General Hospital, National and Kapodistrian University of Athens, Ypsilantou 45-47, 10675 Athens, Greece.

**References**

1. Schilder L, Nurmoohamed SA, Ter Wee PM, Pauw NJ, Gribes AR, Beishuizen A, et al. The plasma level and biomarker value of neutrophil gelatinase-associated lipocalin in critically ill patients with acute kidney injury are not affected by continuous venovenous hemofiltration and anticoagulation applied. Crit Care. 2014;18:R78.
2. Mårtensson J, Bell M, Oldner A, Xu S, Venge P, Martling CR. Neutrophil gelatinase-associated lipocalin in adult septic patients with and without acute kidney injury. Intensive Care Med. 2010;36:1333–40.
3. Paragas N, Qiu A, Zhang Q, Samstein B, Deng SX, Schmidt-Ott KM, et al. The Ngal reporter mouse detects the response of the kidney to injury in real time. Nat Med. 2011;17:216–22.
4. Schmidt-Ott KM, Mori K, Li JY, Kalandadze A, Cohen DJ, Devarajan P, et al. Dual action of neutrophil gelatinase-associated lipocalin. J Am Soc Nephrol. 2007;18:407–13.
5. Mishra J, Mori K, Ma Q, Kelly C, Yang J, Mitsnefes M, et al. Amelioration of ischemic acute renal injury by neutrophil gelatinase-associated lipocalin. J Am Soc Nephrol. 2004;15:3073–82.